Published in J Leukoc Biol on November 17, 2010
Host-cell sensors for Plasmodium activate innate immunity against liver-stage infection. Nat Med (2013) 2.06
The TLR4 antagonist Eritoran protects mice from lethal influenza infection. Nature (2013) 1.78
5,6-Dimethylxanthenone-4-acetic acid (DMXAA) activates stimulator of interferon gene (STING)-dependent innate immune pathways and is regulated by mitochondrial membrane potential. J Biol Chem (2012) 1.33
Reprogramming of murine macrophages through TLR2 confers viral resistance via TRAF3-mediated, enhanced interferon production. PLoS Pathog (2013) 0.97
Inhibition of pyrimidine biosynthesis pathway suppresses viral growth through innate immunity. PLoS Pathog (2013) 0.93
Salmonella Typhimurium Co-Opts the Host Type I IFN System To Restrict Macrophage Innate Immune Transcriptional Responses Selectively. J Immunol (2015) 0.85
Proteomic response to 5,6-dimethylxanthenone 4-acetic acid (DMXAA, vadimezan) in human non-small cell lung cancer A549 cells determined by the stable-isotope labeling by amino acids in cell culture (SILAC) approach. Drug Des Devel Ther (2015) 0.85
Novel strategies for targeting innate immune responses to influenza. Mucosal Immunol (2016) 0.81
Comparative analysis of viral RNA signatures on different RIG-I-like receptors. Elife (2016) 0.80
The chemotherapeutic agent DMXAA as a unique IRF3-dependent type-2 vaccine adjuvant. PLoS One (2013) 0.80
Characterization of a Novel Human-Specific STING Agonist that Elicits Antiviral Activity Against Emerging Alphaviruses. PLoS Pathog (2015) 0.79
Antiviral Effects of Novel Herbal Medicine KIOM-C, on Diverse Viruses. PLoS One (2015) 0.78
Editorial: One small molecule: a new way to treat the flu? J Leukoc Biol (2011) 0.75
AMP-activated kinase (AMPK) promotes innate immunity and antiviral defense through modulation of stimulator of interferon genes (STING) signaling. J Biol Chem (2016) 0.75
Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA (2003) 31.71
Influenza-associated hospitalizations in the United States. JAMA (2004) 18.23
DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature (2007) 13.56
Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci (1957) 13.46
Multiple sclerosis. N Engl J Med (2000) 12.69
Innate immune recognition of viral infection. Nat Immunol (2006) 9.59
Neuraminidase inhibitors for influenza. N Engl J Med (2005) 7.79
Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet (2005) 5.70
Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009. MMWR Morb Mortal Wkly Rep (2009) 4.36
Disrupting tumour blood vessels. Nat Rev Cancer (2005) 4.35
Global transmission of oseltamivir-resistant influenza. N Engl J Med (2009) 4.34
Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08. Emerg Infect Dis (2009) 4.06
Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res (2009) 3.39
Virus interference. II. Some properties of interferon. Proc R Soc Lond B Biol Sci (1957) 3.32
Regulation of type I interferon gene expression by interferon regulatory factor-3. J Biol Chem (1998) 3.31
Inhibition of respiratory virus infection by locally applied interferon. Lancet (1973) 3.02
Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis (2006) 2.43
Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis. N Engl J Med (2009) 2.24
The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis. J Exp Med (2007) 2.23
Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin Infect Dis (2010) 1.89
Oseltamivir-resistant influenza A pandemic (H1N1) 2009 virus, Hong Kong, China. Emerg Infect Dis (2009) 1.87
The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza. N Engl J Med (2009) 1.86
The cotton rat provides a useful small-animal model for the study of influenza virus pathogenesis. J Gen Virol (2005) 1.49
Novel signaling interactions between proteinase-activated receptor 2 and Toll-like receptors in vitro and in vivo. Mucosal Immunol (2009) 1.39
Adjuvant therapy of melanoma with interferon: lessons of the past decade. J Transl Med (2008) 1.28
5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent. Clin Cancer Res (2006) 1.27
Costimulation modulation uncouples protection from immunopathology in memory T cell responses to influenza virus. J Immunol (2009) 1.18
The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities. Expert Opin Investig Drugs (2010) 1.02
Treatment of epidemic and pandemic influenza with neuraminidase and M2 proton channel inhibitors. Clin Microbiol Infect (2003) 1.01
The results of controlled observations on the prophylaxis of influenza with interferon. Bull World Health Organ (1969) 1.00
Use of neuraminidase inhibitors to combat pandemic influenza. J Antimicrob Chemother (2006) 0.98
Peginterferon-alpha-2a (40 kD): A review of its use in chronic hepatitis B. Drugs (2009) 0.93
Intranasally administered interferon as prophylaxis against experimentally induced influenza A virus infection in humans. J Infect Dis (1987) 0.87
Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients. Clin Cancer Res (2008) 0.86
Measurement of antiviral activity induced by interferons alpha, beta, and gamma. Curr Protoc Immunol (2001) 0.84
Measurement of interferon-mediated antiviral activity of macrophages. Curr Protoc Immunol (2001) 0.77
Influenza research in the Soviet Union--1974. J Infect Dis (1974) 0.77
The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat Immunol (2010) 7.47
Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat Immunol (2011) 6.73
TLR4, but not TLR2, mediates IFN-beta-induced STAT1alpha/beta-dependent gene expression in macrophages. Nat Immunol (2002) 4.63
Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria. Science (2012) 4.20
Distribution and compartmentalization of human circulating and tissue-resident memory T cell subsets. Immunity (2012) 3.21
Cutting edge: Tissue-retentive lung memory CD4 T cells mediate optimal protection to respiratory virus infection. J Immunol (2011) 3.03
Toll receptors, CD14, and macrophage activation and deactivation by LPS. Microbes Infect (2002) 2.90
Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105. Nat Immunol (2005) 2.85
The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis. J Exp Med (2007) 2.23
The CATERPILLER protein monarch-1 is an antagonist of toll-like receptor-, tumor necrosis factor alpha-, and Mycobacterium tuberculosis-induced pro-inflammatory signals. J Biol Chem (2005) 2.21
Selective roles for Toll-like receptor (TLR)2 and TLR4 in the regulation of neutrophil activation and life span. J Immunol (2003) 2.18
Immunologic consequences of Francisella tularensis live vaccine strain infection: role of the innate immune response in infection and immunity. J Immunol (2006) 2.16
Dysregulation of LPS-induced Toll-like receptor 4-MyD88 complex formation and IL-1 receptor-associated kinase 1 activation in endotoxin-tolerant cells. J Immunol (2002) 2.11
Francisella tularensis live vaccine strain induces macrophage alternative activation as a survival mechanism. J Immunol (2008) 2.06
Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. Gastroenterology (2008) 1.98
Toll-like receptor 2-mediated signaling requirements for Francisella tularensis live vaccine strain infection of murine macrophages. Infect Immun (2007) 1.98
Role of the phosphatidylinositol 3 kinase-Akt pathway in the regulation of IL-10 and IL-12 by Porphyromonas gingivalis lipopolysaccharide. J Immunol (2003) 1.96
Toll-like receptor 2 is required for inflammatory responses to Francisella tularensis LVS. Infect Immun (2006) 1.93
Overexpression of monocyte chemoattractant protein 1 in the brain exacerbates ischemic brain injury and is associated with recruitment of inflammatory cells. J Cereb Blood Flow Metab (2003) 1.93
Analysis of TLR4 polymorphic variants: new insights into TLR4/MD-2/CD14 stoichiometry, structure, and signaling. J Immunol (2006) 1.88
TLR4/MyD88/PI3K interactions regulate TLR4 signaling. J Leukoc Biol (2009) 1.87
Tolerance to microbial TLR ligands: molecular mechanisms and relevance to disease. J Endotoxin Res (2006) 1.86
Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid. J Immunol (2013) 1.85
Distinct mutations in IRAK-4 confer hyporesponsiveness to lipopolysaccharide and interleukin-1 in a patient with recurrent bacterial infections. J Exp Med (2003) 1.83
An angiogenic switch in macrophages involving synergy between Toll-like receptors 2, 4, 7, and 9 and adenosine A(2A) receptors. Am J Pathol (2003) 1.80
Role of TLR4 tyrosine phosphorylation in signal transduction and endotoxin tolerance. J Biol Chem (2007) 1.78
The TLR4 antagonist Eritoran protects mice from lethal influenza infection. Nature (2013) 1.78
Control of memory CD4 T cell recall by the CD28/B7 costimulatory pathway. J Immunol (2006) 1.73
Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus. Proc Natl Acad Sci U S A (2011) 1.73
Memory CD4 T cells direct protective responses to influenza virus in the lungs through helper-independent mechanisms. J Virol (2010) 1.72
Contribution of interferon-beta to the murine macrophage response to the toll-like receptor 4 agonist, lipopolysaccharide. J Biol Chem (2006) 1.70
Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2. Proc Natl Acad Sci U S A (2009) 1.67
Macrophage proinflammatory response to Francisella tularensis live vaccine strain requires coordination of multiple signaling pathways. J Immunol (2008) 1.64
Association of TLR4 polymorphisms with symptomatic respiratory syncytial virus infection in high-risk infants and young children. J Immunol (2007) 1.61
Antigen-specific B-1a antibodies induced by Francisella tularensis LPS provide long-term protection against F. tularensis LVS challenge. Proc Natl Acad Sci U S A (2009) 1.61
A repertoire-independent and cell-intrinsic defect in murine GVHD induction by effector memory T cells. Blood (2011) 1.60
The TLR4 agonist, monophosphoryl lipid A, attenuates the cytokine storm associated with respiratory syncytial virus vaccine-enhanced disease. Vaccine (2006) 1.57
Toll-like receptors in health and disease: complex questions remain. J Immunol (2003) 1.57
TLR4 signaling is coupled to SRC family kinase activation, tyrosine phosphorylation of zonula adherens proteins, and opening of the paracellular pathway in human lung microvascular endothelia. J Biol Chem (2008) 1.55
Tobacco smoking inhibits expression of proinflammatory cytokines and activation of IL-1R-associated kinase, p38, and NF-kappaB in alveolar macrophages stimulated with TLR2 and TLR4 agonists. J Immunol (2007) 1.53
Gliadin stimulation of murine macrophage inflammatory gene expression and intestinal permeability are MyD88-dependent: role of the innate immune response in Celiac disease. J Immunol (2006) 1.51
Enhancing alloreactivity does not restore GVHD induction but augments skin graft rejection by CD4⁺ effector memory T cells. Eur J Immunol (2011) 1.49
Flagellin of enteropathogenic Escherichia coli stimulates interleukin-8 production in T84 cells. Infect Immun (2003) 1.49
MicroRNAs of the miR-17∼92 family are critical regulators of T(FH) differentiation. Nat Immunol (2013) 1.48
Toll-like receptor 4 and Toll-IL-1 receptor domain-containing adapter protein (TIRAP)/myeloid differentiation protein 88 adapter-like (Mal) contribute to maximal IL-6 expression in macrophages. J Immunol (2002) 1.47
The proteasome: a central regulator of inflammation and macrophage function. Immunol Res (2005) 1.45
Toll-like receptors 2 and 4 activate STAT1 serine phosphorylation by distinct mechanisms in macrophages. J Biol Chem (2003) 1.44
Differential involvement of BB loops of toll-IL-1 resistance (TIR) domain-containing adapter proteins in TLR4- versus TLR2-mediated signal transduction. J Immunol (2005) 1.44
Pivotal advance: activation of cell surface Toll-like receptors causes shedding of the hemoglobin scavenger receptor CD163. J Leukoc Biol (2006) 1.40
Prolonged antigen presentation is required for optimal CD8+ T cell responses against malaria liver stage parasites. PLoS Pathog (2010) 1.39
PAD4-mediated neutrophil extracellular trap formation is not required for immunity against influenza infection. PLoS One (2011) 1.39
Novel phenotypes and migratory properties distinguish memory CD4 T cell subsets in lymphoid and lung tissue. Eur J Immunol (2005) 1.38
Analysis of proteinase-activated receptor 2 and TLR4 signal transduction: a novel paradigm for receptor cooperativity. J Biol Chem (2008) 1.38
Type I IL-4Rs selectively activate IRS-2 to induce target gene expression in macrophages. Sci Signal (2008) 1.37
The proteasome as a lipopolysaccharide-binding protein in macrophages: differential effects of proteasome inhibition on lipopolysaccharide-induced signaling events. J Immunol (2003) 1.35
Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect Immun (2002) 1.34
The FcR gamma subunit and Syk kinase replace the CD3 zeta-chain and ZAP-70 kinase in the TCR signaling complex of human effector CD4 T cells. J Immunol (2003) 1.34
Mice deficient in the CXCR2 ligand, CXCL1 (KC/GRO-alpha), exhibit increased susceptibility to dextran sodium sulfate (DSS)-induced colitis. Innate Immun (2008) 1.34
TLR2 and TLR4 serve distinct roles in the host immune response against Mycobacterium bovis BCG. J Leukoc Biol (2003) 1.33
5,6-Dimethylxanthenone-4-acetic acid (DMXAA) activates stimulator of interferon gene (STING)-dependent innate immune pathways and is regulated by mitochondrial membrane potential. J Biol Chem (2012) 1.33
Pulse-oximetry accurately predicts lung pathology and the immune response during influenza infection. Virology (2009) 1.32
The Asp299Gly polymorphism alters TLR4 signaling by interfering with recruitment of MyD88 and TRIF. J Immunol (2012) 1.31
Toll-like receptor 7 is required for effective adaptive immune responses that prevent persistent virus infection. Cell Host Microbe (2012) 1.29
Bacillus anthracis spores and lethal toxin induce IL-1beta via functionally distinct signaling pathways. Eur J Immunol (2008) 1.27
Regulation of gene expression in mouse macrophages stimulated with bacterial CpG-DNA and lipopolysaccharide. J Leukoc Biol (2002) 1.25
Up-regulation of human monocyte CD163 upon activation of cell-surface Toll-like receptors. J Leukoc Biol (2006) 1.24
Transcriptional regulation of murine IL-33 by TLR and non-TLR agonists. J Immunol (2012) 1.22
Key inflammatory signaling pathways are regulated by the proteasome. Shock (2006) 1.21
New insights for development of a safe and protective RSV vaccine. Hum Vaccin (2010) 1.18
Costimulation modulation uncouples protection from immunopathology in memory T cell responses to influenza virus. J Immunol (2009) 1.18
Divergent generation of heterogeneous memory CD4 T cells. J Immunol (2006) 1.17
CD103 expression is required for destruction of pancreatic islet allografts by CD8(+) T cells. J Exp Med (2002) 1.16
T cell rewiring in differentiation and disease. J Immunol (2003) 1.16
Induced pluripotent stem cell model recapitulates pathologic hallmarks of Gaucher disease. Proc Natl Acad Sci U S A (2012) 1.15
Memory T cells in transplantation: generation, function, and potential role in rejection. Am J Transplant (2004) 1.15
Surgical downstaging in an open-label phase II trial of denosumab in patients with giant cell tumor of bone. Ann Surg Oncol (2015) 1.14
Differential activation of human TLR4 by Escherichia coli and Shigella flexneri 2a lipopolysaccharide: combined effects of lipid A acylation state and TLR4 polymorphisms on signaling. J Immunol (2008) 1.14
Mastoparan, a G protein agonist peptide, differentially modulates TLR4- and TLR2-mediated signaling in human endothelial cells and murine macrophages. J Immunol (2005) 1.14
Toll-like receptor (TLR)2 and TLR4 agonists regulate CCR expression in human monocytic cells. J Immunol (2004) 1.12
Signaling control of memory T cell generation and function. Semin Immunol (2004) 1.12
Transcriptional activation of the human inducible nitric-oxide synthase promoter by Kruppel-like factor 6. J Biol Chem (2003) 1.11
Cutting Edge: Differential inhibition of TLR signaling pathways by cell-permeable peptides representing BB loops of TLRs. J Immunol (2007) 1.11
The IFN-inducible GTPase LRG47 (Irgm1) negatively regulates TLR4-triggered proinflammatory cytokine production and prevents endotoxemia. J Immunol (2007) 1.11
Overexpression of CD14, TLR4, and MD-2 in HEK 293T cells does not prevent induction of in vitro endotoxin tolerance. J Endotoxin Res (2003) 1.10
Functional plasticity of an antigen-specific memory CD4 T cell population. Proc Natl Acad Sci U S A (2002) 1.10
CTLA4 expression is an indicator and regulator of steady-state CD4+ FoxP3+ T cell homeostasis. J Immunol (2008) 1.08
Identifying and hurdling obstacles to translational research. Nat Rev Immunol (2007) 1.07
Regulation of CD103 expression by CD8+ T cells responding to renal allografts. J Immunol (2004) 1.07
Role of phosphatidylinositol-3 kinase in transcriptional regulation of TLR-induced IL-12 and IL-10 by Fc gamma receptor ligation in murine macrophages. J Immunol (2007) 1.07
Gene transfection and expression in resting and activated murine CD4 T cell subsets. J Immunol Methods (2003) 1.07
Antigen-specific memory in B-1a and its relationship to natural immunity. Proc Natl Acad Sci U S A (2012) 1.07
Vibrio cholerae flagellins induce Toll-like receptor 5-mediated interleukin-8 production through mitogen-activated protein kinase and NF-kappaB activation. Infect Immun (2008) 1.07